Subtitle
Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation.
Subtitle
Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation.
Proto therapy Time
October 2019
Executive summary
With the National Cancer Database for T1-2N0 HCC patients receiving PBT or SBRT, a total of 71 patients received PBT and 918 patients received SBRT were analyzed.
The study reported that PBT was associated with longer survival than SBRT, despite being delivered to HCC patients with multiple poor prognostic factors. PBT may also allow for safer BED escalation, which also independently associated with outcomes.
Top cancer treatments
Related contents
Proton Therapy Publication
September 2024
Cost-utility analysis of proton beam therapy for locally advanced esophageal cancer in Japan.
Proton Therapy Publication
September 2024
Particle therapy in gastrointestinal cancer-a narrative review.
Proton Therapy Publication
September 2024
Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study.
Proton Therapy Publication
June 2024
Effectiveness and Safety of Carbon Ion Radiotherapy in Solid Tumors: A Systematic Review and Meta-Analysis.
Proton Therapy Publication
June 2024
Optimizing GRID and Lattice Spatially Fractionated Radiation Therapy: Innovative Strategies for Radioresistant and Bulky Tumor Management.
Proton Therapy Publication
May 2024
PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement.
Proton Therapy Publication
May 2024
Comparing 90-Day Postoperative Mortality After Neoadjuvant Proton-Based Versus Photon-Based Chemoradiotherapy for Esophageal Cancer.
Proton Therapy Publication
May 2024
Proton Beam Radiotherapy as a Curative Alternative to Radiofrequency Ablation for Newly Diagnosed Hepatocellular Carcinoma.
Proton Therapy Publication
May 2024
Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma.